The discovery of the diarylquinoline TMC207 (R207910) reported in Science in 2005 caused excitement not only because of its strong bactericidal activity in vitro but also because mouse studies indicate that it has the potential to shorten treatment duration of both Drug Sensitive (DS) and Multi-Drug Resistant (MDR) TB. Its discovery revealed a new target, namely, ATP synthase. ATP synthase was clinically validated as a viable target based on the phase 2 trial published in the New England Journal of Medicine (NEJM) in 2009.





Continued Research:



In 2009, a collaboration was initiated between Tibotec and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, responding to the urgent need to accelerate the discovery of new drugs to fight tuberculosis (TB). Both parties collaborate on a discovery program to identify new ATP synthase inhibitors.



Publications:



For a list of scientific references related to TMC207 in the published literature, please click

here.